Efficacy of fluticasone exhalation delivery system in the management of chronic rhinosinusitis : what is the evidence?
Background Intranasal steroids have become part of the mainstay in the long‐term management of chronic rhinosinusitis. A long‐standing problem remains in efficient and easy‐to‐use delivery of topical corticosteroids to the nasal mucosa. Currently available means of intranasal steroid delivery include sprays, which are generally limited to treating the anterior nasal cavity, and rinses, which are not FDA‐approved for this indication. The exhalation delivery system is a novel method of delivering fluticasone to the deeper areas within the nasal cavities, including the posterior nasal cavity and middle and superior meatuses. Methods Comprehensive literature review. Results Recent large scale studies have suggested its efficacy and safety in the use of patients with both chronic sinusitis with polyposis and without polyps. Specifically, studies have demonstrated decreased Sinonasal Outcome Test scores of 20 points following treatment, as well as improvement of polyp grade by 1 or more point in more than 60% of patients. Furthermore, among patients with nasal polyps, there was approximately 60‐70% decreased indication for surgery following EDS‐FLU use. Conclusion EDS‐FLU is an important adjunct therapy for sinonasal inflammatory disease..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
International Forum of Allergy & Rhinology - 9(2019), S1, Seite S16-S21 |
| Beteiligte Personen: |
Kuan, Edward C. [VerfasserIn] |
|---|
| Anmerkungen: |
© 2019 ARS‐AAOA, LLC |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1002/alr.22340 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY001252739 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY001252739 | ||
| 003 | DE-627 | ||
| 005 | 20230307102036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2019 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/alr.22340 |2 doi | |
| 028 | 5 | 2 | |a ALR_ALR22340.xml |
| 035 | |a (DE-627)WLY001252739 | ||
| 035 | |a (WILEY)ALR22340 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Kuan, Edward C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of fluticasone exhalation delivery system in the management of chronic rhinosinusitis |b what is the evidence? |
| 264 | 1 | |c 2019 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2019 ARS‐AAOA, LLC | ||
| 520 | |a Background Intranasal steroids have become part of the mainstay in the long‐term management of chronic rhinosinusitis. A long‐standing problem remains in efficient and easy‐to‐use delivery of topical corticosteroids to the nasal mucosa. Currently available means of intranasal steroid delivery include sprays, which are generally limited to treating the anterior nasal cavity, and rinses, which are not FDA‐approved for this indication. The exhalation delivery system is a novel method of delivering fluticasone to the deeper areas within the nasal cavities, including the posterior nasal cavity and middle and superior meatuses. Methods Comprehensive literature review. Results Recent large scale studies have suggested its efficacy and safety in the use of patients with both chronic sinusitis with polyposis and without polyps. Specifically, studies have demonstrated decreased Sinonasal Outcome Test scores of 20 points following treatment, as well as improvement of polyp grade by 1 or more point in more than 60% of patients. Furthermore, among patients with nasal polyps, there was approximately 60‐70% decreased indication for surgery following EDS‐FLU use. Conclusion EDS‐FLU is an important adjunct therapy for sinonasal inflammatory disease. | ||
| 700 | 1 | |a Kovacs, Alexander J. |4 aut | |
| 700 | 1 | |a Workman, Alan D. |4 aut | |
| 700 | 1 | |a Bosso, John V. |4 aut | |
| 700 | 1 | |a Adappa, Nithin D. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International Forum of Allergy & Rhinology |g 9(2019), S1, Seite S16-S21 |w (DE-627)WLY001250981 |x 20426984 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2019 |g number:S1 |g pages:S16-S21 |g extent:6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2019 |e S1 |h S16-S21 |g 6 | ||